LY3499446

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3499446, covering 2021-11-24 to 2021-11-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation [Phase 1, Phase 2]